Brain tumors cannot always be successfully treated with conventional therapies. A team from Empa and the hospital network HOCH Health Ostschweiz is therefore developing nanozymes that can attack ...

A Phase 1 trial shows a personalized DNA vaccine (GNOS-PV01) is safe and doubles survival rates for aggressive glioblastoma.

Survival rate surpasses historical outcomes in a small phase I study ...

A personalized vaccine to treat glioblastoma, a fast-growing and incurable brain cancer that affects four in 100,000 people ...

Participants in a clinical trial lived longer years longer after increased immune response to glioblastoma slowed progression ...

All types of brain cancers collectively have a five-year survival rate of just 33%, according to the National Cancer ...

A new grant from the American Cancer Society (ACS) will fund research into a new strategy for targeting glioblastoma at MUSC Hollings Cancer Center. Glioblastoma is an aggressive type of brain cancer.

Glioblastoma is the most aggressive form of brain cancer, with survival often measured in months despite treatment.

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2026, and ...

Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in ...

Hello, and welcome to Nuvation Bio's First Quarter 2026 Financial Results and Corporate Update Call. Today's call is being recorded, and a replay will be available on the company's website. [Operator ...